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Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID), with a
preferential action on the cyclooxygenase (COX)-2 isoform of COX and a long
duration of action. It is classified chemically as a member of the sulphona-
mide subgroup of coxibs. Mavacoxib is highly lipid but very poorly water sol-
uble. In the dog, the pharmacokinetic (PK) profile comprises very slow body
clearance, long elimination half-life and a relatively large distribution volume.
Biotransformation and renal excretion are very limited, and elimination
occurs primarily by biliary secretion and excretion of unchanged drug in fae-
ces. The PK profile of mavacoxib differs quantitatively between young healthy
dogs (Beagles and mongrels) and clinical cases with osteoarthritis (OA). In
OA dogs, mavacoxib exhibits a much longer terminal half-life, associated
principally with their greater median body weight compared with dogs used
in preclinical studies. There is also some evidence of breed differences and a
small effect of age on mavacoxib PK in the OA canine population. The phar-
macodynamics (PD) of mavacoxib has been established: (i) in whole blood
assays at the molecular level (inhibition of COX-1 and COX-2 isoforms); (ii)
in preclinical models of inflammation and pain; and (iii) in clinical OA sub-
jects treated with mavacoxib. The dosage schedule of mavacoxib for clinical
use has been determined by owner and veterinary clinical assessments and is
supported by integration of PK and PD preclinical data with clinical responses
in canine disease models and in dogs with naturally occurring OA. The dos-
age regimen has been further confirmed by correlating levels of inhibition of
COX isoforms in in vitro whole blood assays with plasma concentrations of
mavacoxib achieved in OA dogs. In addition to the specific properties of ma-
vacoxib, some general aspects of the PK and PD of other agents of the NSAID
group, together with pathophysiological and clinical aspects of OA, are
reviewed, as a basis for correlating with the safety and efficacy of mavacoxib
in therapeutic use. Integration of PK and PD data suggests that the recom-
mended dosage regimen of 2 mg/kg bw once for 14 days, followed by admin-
istration at monthly intervals, is optimal from both efficacy and safety
perspectives and is further confirmed by clinical field studies.
(Paper received 12 September 2013; accepted for publication 19 October
2014)
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COMPARATIVE PHARMACOLOGY, TOXICOLOGY AND
THERAPEUTICS OF MAVACOXIB
Only limited comparison of mavacoxib with other agents of
the nonsteroidal anti-inflammatory drug (NSAID) class is
possible in this review. The reader is referred to Berg
and Budsberg (2005), Lascelles et al. (2005), Papich (2008),
Lees (2009), KuKanich et al. (2012) and Monteiro-Stea-
gall et al. (2013) for comparative reviews on NSAIDs in the
dog.
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CHEMICAL STRUCTURE AND PHYSICO-CHEMICAL
PROPERTIES OF MAVACOXIB
Mavacoxib is a NSAID of the coxib subgroup. Chemically, it is
a substituted sulphonamide, structurally similar to celecoxib
(Penning et al., 1997) and differing only in the substitution of
a methyl group by a fluorine atom (Fig. 1). The chemical
name is 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl]-benzenesulfonamide. There are five crystalline forms of
mavacoxib (I–V), distinguished by powder X-ray diffraction.
Form I is used in the commercial product; it is an anhydrous,
nonsolvated and nonhygroscopic form. Mavacoxib is chemi-
cally and physically stable under ambient conditions. It is a
weak organic base; the pKa is 9.57. Its physico-chemical prop-
erties include very low water solubility at room temperature
(6 lg/mL) and very high lipid solubility. The XLOGP3 value is
3.1. According to Biopharmaceutics Classification System
(Amidon et al., 1995; Martinez et al., 2002; Yu et al., 2002),
mavacoxib would likely be classified as a Class II compound,
that is a poorly water soluble but highly permeable drug. It is
therefore expected that mavacoxib in solution will be readily
absorbed from the gastrointestinal tract (g.i.t.). The incomplete
bioavailability reported in some trials (vide infra) is probably
due to incomplete solubility, relating to food availability at the
time of dosing. This is also relevant to enterohepatic recycling,
as a study using radio-labelled mavacoxib demonstrated that
55% of parent mavacoxib can be detected in bile.
CLINICAL INDICATIONS AND DOSAGE
Mavacoxib is indicated for the treatment of pain and inflamma-
tion in dogs with osteoarthritis (OA), aged 12 months or older
(EMA, 2008). Commercially, mavacoxib is available as
chewable tablets in five strengths, ranging from 6 to 95 mg
per tablet. It is contraindicated in dogs weighing <5 kg. The
manufacturer’s recommended dosage is 2 mg/kg, administered
with an interval of 14 days between doses 1 and 2 and inter-
vals of 28 days for subsequent doses. The maximum duration
of treatment is 6.5 months.
PRECLINICAL AND POPULATION
PHARMACOKINETICS
Preclinical pharmacokinetics in Beagle and mongrel dogs
The pharmacokinetic (PK) profile of mavacoxib in Beagle dogs
was described by Cox et al. (2010). Body clearance was very
slow (0.045 mL/kg/min) and the volume of distribution rather
large (1.64 L/kg), explaining the long elimination half-life of
17.3 days (Table 1). Across three groups of dogs administered
mavacoxib (intravenous fasted, oral fasted and oral fed), the
range of individual half-life was 9.6–38.6 days. Bioavailability
was significantly greater at 87% in fed dogs compared with
46% in fasted animals (Table 1). Increased bioavailability in
fed compared with fasted dogs has also been reported for other
sulphonamide coxibs, including celecoxib (Paulson et al.,
2001) and deracoxib (Novartis Animal Health, 2007). These
drugs have the common properties of low water and high lipid
solubility, thus belonging to Class II (poorly soluble, highly per-
meable) of the Biopharmaceutics Classification System (Marti-
nez et al., 2002).
In addition to high bioavailability of mavacoxib in fed dogs,
two further aspects of the absorption pattern are of interest.
First, there was rapid attainment of a plasma concentration of
0.4 lg/mL, shown to provide a good degree of analgesia in pre-
clinical models (vide infra). The mean concentration in fed dogs
1 h after dosing was 2.1 lg/mL and this was 80% of Cmax. The
data further suggest that, based on trough concentrations of
Fig. 1. Chemical structure of mavacoxib.
Table 1. Pharmacokinetics of mavacoxib in Beagle dogs (LS mean and
95% confidence intervals, n = 10)*
Variable (units) Route LS mean (CI)
Cl (mL/kg/min)† IV 0.045 (0.035, 0.055)
t½ (days) (fasted dogs) IV 17.3 (15.0, 20.5)
t½ (days) (fed dogs) Oral 15.5 (13.6, 18.0)
t½ (days) (fasted dogs) Oral 19.3 (16.5, 23.4)
Vdss (L/kg) IV 1.64 (1.41, 1.87)
Plasma protein binding (%) IV >98
Tmax (h) (fasted dogs) IV 0.55 (25.3, 26.4)
Tmax (h) (fed dogs) Oral 17.4 (8.4, 43.2)
Tmax (h) (fasted dogs) Oral 67.4 (41.6, 93.2)
F (%) (fed dogs) Oral 87 (64, 120)
F (%) (fasted dogs) Oral 46 (34, 63)
Cl, body clearance; t½, elimination half-life; Vdss , volume of distribution
at steady-state; Tmax, time of maximum concentration; F, bioavailabil-
ity. *Data from Cox et al. (2010). †Clearance value can be compared
with the value of 5.8 mL/kg/min defined by Toutain and Bousquet-
Melou (2004a) as a ‘low’ value for dogs weighing 10–20 kg. This indi-
cates the very low clearance rate of mavacoxib.
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mavacoxib, effective analgesia would be provided for the dogs in
this PK study for 28 days (oral fed) and 21 days (oral fasted). In
addition, in both fed and fasted orally dosed dogs and also after
intravenous dosing, there were multiple early peaks in plasma
mavacoxib concentration. Causes are unknown, but a possible
partial explanation could be repeated enterohepatic recycling.
Cox et al. (2010) also described the PK of multiple oral
doses (4 mg/kg) of mavacoxib in Beagle dogs, administered
on days 0, 14, 42 and 70. Although Cmax was lower after
dose 1, trough and average concentrations of mavacoxib
were similar for all four doses (Table 2), indicating achieve-
ment of steady-state PK after the second dose. Concentrations
predicted to provide good analgesic responses (i.e., >0.4 lg/
mL), vide infra were provided by trough concentrations after
all four doses.
Cox et al. (2010) reported on dose proportionality of the PK
of mavacoxib in Beagle dogs with single oral doses of 2, 4 and
12 mg/kg. This was demonstrated for AUC and Cmax. They
also described dose proportionality in mongrel dogs in a multi-
ple dose (5, 15 and 25 mg/kg), multiple dosing (days 0, 14,
42, 70, 98, 126 and 154 days) study. To maximize systemic
drug exposure, each dog was allowed access to food within
1–2 h after each dose. Dose proportionality for maximum and
average concentrations and also AUCs was demonstrated
across the dosage range of 5–25 mg/kg for both first and final
administered doses. The dose normalized steady-state AUCs val-
ues in this study were similar to AUC∞ values determined in
fed dogs in the single dose absolute bioavailability study.
Therefore, the data suggest that the PK profile of orally admin-
istered mavacoxib is similar in young Beagles and young mon-
grels of similar body weights.
Plasma protein binding
The binding to plasma protein of mavacoxib exceeds 98% of
total concentration (Cox et al., 2010). Assuming linear binding
as demonstrated by Cox et al. (2010), the total and free con-
centrations are proportional to an unbound (fu) factor and the
same maintenance dose can be accurately computed, based
either on the total or on the free plasma clearance (Toutain
and Bousquet-Melou (2004a), thus:
Maintenance monthly dose ¼ Monthly Plasma ðtotalÞ clearance
 Target ðtotalÞ concentration
or
Maintenance monthly dose ¼ Monthly Plasma ðfreeÞ clearance
 Target ðfreeÞ concentration.
Population pharmacokinetics in osteoarthritic dogs
Martinez and Modric (2010) have pointed out that ‘when PK
data are generated in small groups of normal healthy animals,
it is often assumed that these data represent the drug’s PK
characteristics across the intended patient population’. The
statement of Martinez and Modric highlights the importance to
extrapolate PK data derived from young healthy animals to
older and possibly diseased populations of animals with great
caution. The population inferential value of those data is rarely
considered. Cox et al. (2011) described population PK data for
mavacoxib in two field trials, incorporating primarily elderly
(median age = 10 years) large-breed dogs, all diagnosed with
OA. In both trials, dogs received the commercial tablet formu-
lation at dosage of 4 mg/kg for seven doses (trial 1) and 2 mg/
kg for five doses (trial 2). The dosing interval was 2 weeks
between first and second doses, then monthly thereafter and
up to seven doses per animal were administered. Mavacoxib
trough concentrations in plasma were determined on a total of
1317 samples from 286 dogs. The population PK analysis was
undertaken using the nonlinear mixed effect modelling pro-
gramme NONMEM v. 6.1.0. (ICON, Hanover, MD, USA), incorpo-
rating various subject demographic variables, including age,
sex, breed and weight. The contribution of each explanatory
variable was assessed in a series of stepwise regressions, in
which the explanatory variables were removed from the full
model and the increase in the objective function was evalu-
ated. The predictive performance of the final model was evalu-
ated by Monte Carlo simulations, and a large majority of
observations were fitted well by the selected model.
In the final model, clearance (Cl) and volume of distribution
(Vd), each scaled by bioavailability (F), were as follows:
Cl/F = 1.35 L/day (0.039 L/day/kg) with between subject var-
iability (BSV) = 46.9%; Vd/F = 85.7 L (2.45 L/kg) with
BSV = 19.4%. Body weight was the primary factor predicting
both variables, but the model also predicted smaller effects of
age and breed on Cl/F (but not Vd/F). The model for a typical
dog, weighing 35 kg and 10 years old, predicted values of Cl/F
and Vd/F, which were power functions of body weight
with coefficients of 0.787 and 0.981, respectively. Thus,
Cl/F = 1.35 9 (WT/35)0.787 9 (Age/10)0.215 9 (1 + 0.314
9 Breed) L/day, where breed is an indicator variable with a
value of 1 for Labrador retrievers or German shepherds, but 0
otherwise and Vd/F = 85.7 9 (WT/35)
0.981.
The mean terminal half-life (t½) determined from empirical
Bayes estimates for 286 dogs was 44 days and t½ increased
Table 2. Maximum and trough concentrations of mavacoxib over the
dosing interval in Beagle dogs after multiple oral doses at a dosage of
4 mg/kg (LS mean and 95% confidence intervals, n = 9)*
Dose number (dosing
study day)
Cmax [LS mean (CI)]
(lg/mL)
Ctrough [LS mean (CI)]
(lg/mL)
1 (1) 1.66 (1.20, 2.28) 0.96 (0.72, 1.28)
2 (14) 3.32 (2.70, 4.08) 0.89 (0.67, 1.18)
3 (42) 2.86 (2.15, 3.82) 0.83 (0.62, 1.10)
4 (70) 2.71 (2.06, 3.58) 0.77 (0.60, 0.99)
Data from Cox et al. (2010). *Dosing interval was 14 days between
first and second doses and 28 days between subsequent doses.
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with body weight, but only slightly. The population PK model
was in agreement with data collected in Beagles and mongrels
in preclinical PK studies. Thus, the population PK model pre-
dicted a t½ for a typical laboratory dog (1-year-old 10-kg body
weight) a t½ of 21 days, which is in agreement with the actual
finding of 17 days. The mavacoxib t½ in the typical OA dog
(BW = 35 kg, 10 years old) was 44 days, the greater value
being accounted for mainly by the weight but also by the age
difference. A typical dog was predicted to attain steady-state
plasma concentrations after 4–7 months. However, 4.6% of the
dogs had long half-lives, ranging from 80 to 140 days. In these
dogs, trough concentrations of mavacoxib increased with each
administered dose, so that steady-state was not achieved within
the 6.5 month long study. Prolonged t½ was not associated with
any covariate factor. Cox et al. (2011) postulated that a poly-
morphism of a transporter involved in the biliary clearance of
mavacoxib might account for and be predictive of prolonged t½
in a small proportion of geriatric large-breed OA dogs.
Determination of an upper bound for maintenance dose for
mavacoxib in OA dogs
The selection of a maintenance dose for NSAIDs is a difficult
task and, at first consideration, the optimal dose is the highest
possible dose that is safe for all dogs. For NSAIDs, it is com-
monly reported that the plasma concentration for which COX-
1 inhibition is <20% (i.e., the IC20) is a safe plasma concentra-
tion for g.i.t toxicity (vide infra); for mavacoxib, the IC20 for
COX-1 from a whole blood assay was 2.46 lg/mL. The corre-
sponding upper limit for a maintenance dose administered at
28 day intervals (the selected clinical dosing interval) can be
estimated by solving the population equation Cl/F, CL/F being
the only PK parameter controlling internal drug exposure.
Considering dogs aged 10 years and of 10, 20 and 40 kg BW,
the upper bounds of a safe maintenance dose were estimated
to be 3.47, 2.99 and 2.58 mg/kg, respectively, for all canine
breeds. For Labradors and German Shepherds, however, the
predicted upper bound for the maintenance dose is 1.314-fold
higher than for all breeds. Overall, it is suggested that a 2 mg/
kg BW dose, administered at 28-day intervals, is a likely safe
dose for most dogs (see section PKs and adverse events). For a
dose of 2 mg/kg for 10-year-old dogs, predicted average
plasma concentrations over the dosing interval are 1.41, 1.64
and 1.90 lg/mL in dogs weighing 10, 20 and 40 kg, respec-
tively, and they are smaller by a factor of 1.314 for Labrador
and German Shepherd breeds.
Rationale for determination of a dosing interval for mavacoxib in
osteoarthritic dogs
The therapeutic index, which is typically considered as the
ratio of the highest exposure to the drug that results in no
toxicity to the exposure that produces the desired effect (Muller
& Milton, 2012) can be established using the second compo-
nent of a dosage regimen, that is the dosing interval. Estab-
lishing an appropriate dosing interval is essential to ensure
that plasma mavacoxib concentrations fluctuate only within its
therapeutic window, that is within the range of plasma con-
centrations associated with safety and efficacy. The therapeutic
window is delimited by two critical concentrations: a lower
concentration below which the probability of achieving ade-
quate efficacy is too low and an upper concentration above
which the risk of side effects occurring outweighs the potential
benefit from any additional therapeutic effect (Rowland & To-
zer, 1995). For most NSAIDS, the therapeutic window is con-
sidered to be rather narrow, although this varies between
drugs and variation occurs for individual animals also. The
limits of upper and lower concentration are not known with
precision for any NSAID including mavacoxib but, as a general
rule, Rowland and Tozer (1995) recommend for this drug class
that the upper and lower limits differ by a factor of no more
than 2 or 3. The plasma concentration fluctuations between
Cmax and Cmin can be predicted from the dosing interval (a
decision for the clinician) and the plasma half-life (a drug prop-
erty; see also Toutain & Bousquet-Melou, 2004b for details).
The dosing interval should be selected to ensure that plasma
concentration fluctuates minimally from the efficacious steady-
state plasma concentration, while the dosing interval must be
compatible with the owner’s routine to guarantee dosing com-
pliance (Lees & Maddison, 2006). When dosing interval is
small relative to half-life, the amplitude of fluctuation in
plasma concentration will likewise be small.
For an individual dog with a dosing interval of 28 days and
a t½ also of 28 days, it can be demonstrated that Cmax/
Cmin = 2. In the case of an animal with t½ = 78 days and
s = 28 days, R = 4.54 and Cmax/Cmin = 1.28 under steady-
state conditions. Therefore, for only a minority of dogs in the
clinical population (with t½ < 28 days) is the Cmax/Cmin ratio
predicted to yield a value >2.
The actual dose interval selected of 28 days therefore yields
a Css, max/Css, min ratio of the order of 1.6, which may be
regarded as acceptably small from both efficacy and safety per-
spectives. These calculations apply for any maintenance dose
(actually 2 mg/kg for mavacoxib), a fixed dosing interval of
28 days, and a clinical population derived mean t½ of 40 days.
From the population parameters, the steady-state Cmax and
Cmin can be also computed; for a typical OA dog of 35 kg BW,
for a maintenance dose of 2 mg/kg every 28 days and an half-
life of 40 days, the predicted Css, max is 2.08 lg/mL and the
predicted Css, min is 1.28 lg/mL giving the expected Css, min/Css,
min ratio of 1.6 for the therapeutic window. It is interesting to
note that this computed minimal plasma concentration in
steady-state condition is equal to the IC80 of COX-2 inhibition,
as determined from a whole blood assay (vide infra, Table 3),
suggesting that trough concentrations of mavacoxib signifi-
cantly inhibit COX-2.
Metabolism and excretion
The metabolism and excretion patterns of mavacoxib adminis-
tered intravenously or orally have been established in
14C-radiolabel studies in Beagle dogs (M. Stegemann, unpub-
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lished data). For plasma concentration, mavacoxib parent com-
pound accounted for at least 90% of total concentration at all
times and at least 95% 72 h after dosing. Expressed as a per-
centage of orally administered dose, the daily excretion of total
radio-labelled residue was of the order of 0.2–0.4% in urine
and 0.7–1.4% in faeces. In faeces, most of the residue (>58%)
was parent drug; in urine, most was metabolites (≤9% of par-
ent drug). The principal elimination mechanism is secretion in
bile. In this respect, the comment of Treinen-Moslen and Kantz
(2006) that ‘acyl glucuronides are plausible proximate toxi-
cants for the small intestinal injury caused by NSAID, based
on their reactivity and extent of secretion into bile’, may be
noted. Obviously, direct effects cause by the parent molecule
can also occur albeit using different mechanisms. However, for
mavacoxib, no acyl glucuronide, that is an electrophilic metab-
olite with sufficient reactivity to adduct proteins and other bio-
molecules, was detected in urine, faeces or bile. This is relevant
to the safety of mavacoxib in relation to any potential entero-
pathic effects (vide infra).
PHARMACODYNAMICS
Inhibition of cyclooxygenases as the principal mechanism of action
of NSAIDs
For COX inhibitors, COX-2 inhibition is considered by most
authors to be the molecular action most related to the thera-
peutically required anti-inflammatory effect, although some
authors have postulated an additional role for COX-1 (Wallace
et al., 1998). Most authors have attributed inhibition of COX-1
to the adverse effects, in relation to perforation, ulceration and
bleeding in the g.i.t. and inhibition of blood clotting pathways.
Nevertheless, it has been argued that both COX-1 and COX-2
contribute to gastric mucosal defence (Wallace, 2008). Indeed,
it is recognized that ‘inhibition of COX-1 bad and inhibition of
COX-2 good’ is an oversimplification of a much more complex
situation. For example, some experimental data indicate that
COX-1 selective inhibitors, as well as the newer drugs produc-
ing selective inhibition of COX-2, have lower ulcerogenic
potential than nonselective inhibitors (Wallace, 2008). More-
over, rodent and canine studies have shown that COX-2 selec-
tive inhibitors may delay the healing of stomach ulcers
(Wallace, 2008; Goodman et al., 2009). This may be relevant
to the safety of COX-2 inhibitors, in the light of the report of
Wooten et al. (2010) that dogs that appear to be clinically nor-
mal may have underlying g.i.t. lesions associated with upregu-
lation of COX-2. On the other hand, Fornai et al. (2014), in a
study of small bowel integrity in rats, suggested that nonselec-
tive NSAIDs and etoricoxib can induce enteropathy through a
topical action, whereas celecoxib lacked similar detrimental
actions. The selectivity profile of COX-1/COX-2 inhibition by
test drugs and the related effects on prostaglandin production
did not appear to play a major role in the pathogenesis of
enteropathy.
It is possible that selective/preferential COX-2 inhibitors at
recommended dosage might exacerbate hypercoagulable states.
However, laboratory data in healthy Beagle dogs demonstrate
that a dose of 10 mg mavacoxib/kg BW (59 the label dose)
had no effect on platelet function as determined by buccal
mucosal bleeding time 16 days after administration (Kraut-
mann et al.,2009). Moreover, the precise consequences of
COX-1 and COX-2 inhibition in the canine kidney have yet to
be resolved (Papich, 2008; KuKanich et al., 2012). It is clear
that there are species differences in terms of the extent and dis-
tribution of COX-2 expression in the kidney. For example, in
the dog and rat, the macula densa expresses COX-2 and vol-
ume depletion leads to marked upregulation of this protein
whereas in the monkey and in human, no COX-2 expression
can be detected (Khan et al., 1998) even on volume depletion
of monkeys. In the dog, chronic treatment with furosemide
and COX-2 preferential inhibitors (carprofen and etodolac) led
to a reversible reduction in GFR (Surdyk et al., 2012), suggest-
ing that COX-2 plays a role in sustaining GFR in volume
depleted dogs, although the effect of nonselective COX inhibi-
tors in this setting has not been studied.
Nevertheless, for efficacy the greater the amount of time
within the interdosing interval that COX-2 can be substantially
inhibited (vide infra), while COX-1 is relatively unaffected, the
safer and more effective the dosage regimen is likely to be, at
least for g.i.t. toxicity, for healthy tissue and inhibition of blood
clotting (Mitchell & Warner, 1999; Warner et al., 1999; Lees
et al., 2004).
Cyclooxygenase-2 is formed in response to tissue injury, irre-
spective of cause (Seibert et al., 1994; Crofford, 1997; Zhang
et al., 1997; Claria, 2003). The initial expectation was that
selective COX-2 inhibitors would be free of the side effects com-
monly associated with classical NSAIDs, which generally are
nonselective COX inhibitors (Masferrer et al., 1994). However,
much subsequent research has identified COX-2 constitutively
in several organs, including the spinal cord, bone, joints, eye,
Table 3. Potency of mavacoxib and potency ratios of mavacoxib and
carprofen in in vitro canine whole blood assays
Magnitude of
inhibition
Mavacoxib inhibition of
COX-1 (lg/mL)*
Mavacoxib inhibition
of COX-2 (lg/mL)†
IC20 2.46 0.169
IC50 8.73 0.394
IC80 48.44 1.28
Potency ratios COX-1:COX-2
Mavacoxib Carprofen
IC20COX-1:IC20COX-2 14.5:1 10.9:1
IC50COX-1:IC50COX-2 22.1:1 17.2:1
IC80COX-1:IC80COX-2 37.8:1 30.8:1
IC20COX-1:IC80COX-2 1.92:1 1.95:1
For mavacoxib, all differences between COX-1 and COX-2 were signifi-
cant (P < 0.0001). Potency ratio differences between carprofen and
mavacoxib were nonsignificant. *Assay based on blood allowed to clot
for 45 min under standard conditions. †Assay based on induction and
activation of COX-2 by Escherichia coli derived lipopolysaccharide with
incubation time of 21 h.
© 2014 John Wiley & Sons Ltd
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kidney, pyloric and duodenal mucosa and vascular endothelial
cells (Flower, 2003; Papich, 2008; Wooten et al., 2008,
2009). The precise roles of constitutively expressed COX-2 in
tissues are the subject of ongoing research (Flower, 2003).
Nevertheless, the general finding from many preclinical and
clinical studies in several species has been that COX-2 selective
drugs have represented a significant therapeutic advance from
a g.i.t. safety perspective (KuKanich et al., 2012). While it has
to be acknowledged that controlled studies in dogs comparing
the gastrointestinal safety of COX-2 selective with nonselective
NSAIDs are not available, it is generally accepted that KuKa-
nich’s observations extrapolate to the situation in dogs as well.
All coxibs are, to varying degrees, selective or preferential
COX-2 inhibitors. For mavacoxib, the basis for the selectivity is
indicated in Fig. 2, which illustrates diagrammatically the ste-
ric hindrance, arising from its molecular conformation. This
limits entry through the channel of access to the acid recogni-
tion and acetylation sites of the COX-1 molecule. For compara-
tive purposes, the entry of ketoprofen, a nonselective COX
inhibitor in the dog, into both sites, is also illustrated.
In vitro and ex vivo whole blood assays have been developed
by many groups to determine concentration–response relation-
ships of NSAIDs for COX-1 and COX-2 inhibition (Warner
et al., 1999; Brideau et al., 2001; Giraudel et al., 2005a,
2009). This has allowed the following: (i) potency determina-
tion expressed as percentage degree of inhibition, usually 50%
(IC50), but also other levels of inhibition (e.g., IC20, IC80, IC95);
and (ii) determination of potency ratios for the two COX iso-
forms, usually expressed as IC50COX-1:IC50COX-2. However,
some groups have preferred consideration of 80–50% inhibi-
tion ratios, because this level of inhibition of COX-2 is required
to ensure good clinical control of pain (Warner et al., 1999;
Lees et al., 2004; Giraudel et al., 2005a,b, 2009). Of relevance
clinically, with respect to the absence of, or minimal effects on,
clotting pathways and the g.i.t. and therefore to safety, is the
magnitude and time course of inhibition of COX-1 throughout
the interdose interval (Lanza et al., 1999).
A precise percentage inhibition of COX-1 for all NSAIDs,
which should not be exceeded on safety grounds, for most
or the entire interdose interval, cannot be stated with cer-
tainty. The ideal might be no inhibition but Lees et al.
(2004) and Giraudel et al. (2005a) have suggested a value
of 20%. Based on these considerations, the latter group has
proposed estimation of the IC20COX-1:IC80COX-2 ratio as a
useful but indirect and approximate indicator of the toxicity:
efficacy ratio of NSAIDs for the g.i.t. However, a consider-
ation particularly relevant to mavacoxib is that the peak
concentration occurs only once every 28 days shortly after
dosing. Whether this infrequent peak together with postpeak
concentrations will provide (other things being equal), a sim-
ilar safety profile as a peak concentration that occurs once
daily for a drug with shorter half-life is an interesting but
unanswered question.
Peripheral and central cyclooxygenase-2 as a target for action
There are no published data on mavacoxib to indicate its prin-
cipal site of action (peripheral or central) in the dog. However,
there is circumstantial evidence that mavacoxib provides thera-
peutic benefit through spinal actions, as well as actions at
Fig. 2. Diagram illustrating access to active
sites of COX-1 and COX-2 by ketoprofen, a
nonelective inhibitor of COX-1 and COX-2 in
the dog, and mavacoxib, a preferential
selective COX-2 inhibitor in the dog.
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peripheral sites of inflammation. Although mavacoxib is highly
bound to proteins, it can easily dissociate, permeate through
the blood–brain barrier and thus be available to any action at
the spinal level (Tanak & Mizojiri, 1999). Moreover, a role for
spinal cord mediated sensitization in the pain of human OA
patients is now widely accepted (Imamura et al., 2008; Read &
Dray, 2008).
COX-2 is expressed constitutively in dorsal horn cells of the
spinal cord and is also induced peripherally at inflammatory
sites in response to tissue damage (Kujubu et al., 1991; Xie
et al., 1991; Crofford et al., 1994; Seibert et al., 1994; Crofford,
1997). The continuous production of pro-inflammatory prosta-
glandins, for example PGE2 by COX-2 peripherally, and probably
centrally also, is believed to be a critical element in maintaining
hyperalgesic responses (Zhang et al., 1997). At the local level,
the source of PGE2 may be infiltrating leucocytes or resident tis-
sue cells (Masferrer et al., 1994). Dirig et al. (1998) proposed
that spinal COX-2 was required for the initiation of thermal hy-
peralgesia, whereas peripheral COX-2 was important in main-
taining hyperalgesia associated with tissue injury.
The expression of COX in synovial tissues of human patients
with rheumatoid arthritis (RA) and (to a lesser degree) OA was
demonstrated in early studies by Sano et al. (1992). Others
demonstrated the selective upregulation of COX-2 mRNA and
COX-2 protein in adjuvant induced arthritis in the rat, soon
after discovery of COX-2 (Anderson et al., 1996). The latter
authors reported inhibition of PGE2 synthesis in this model by
a selective COX-2 inhibitor, accompanied by decreased synovial
inflammation. Koki et al. (2002) reported prominent expression
of COX-2 in human OA knee joints, not only in the synovium
but also in blood vessels and the fibrocartilage of osteophytes.
Amin et al. (1997) reported superinduction of COX-2 in
human OA cartilage. Likewise, COX-2 upregulation occurs in
canine OA of the hip joint in the synovium, joint capsule and
subchondral bone (Lascelles et al., 2009). Martel-Pelletier et al.
(2003) reviewed the extensive literature in this field and con-
firmed the upregulation of COX-2 leading to synthesis of PGE2
in articular chondrocytes and synovial fibroblasts. Laboratory
animal and tissue culture studies have been supported by
reports on the efficacy of coxibs in human OA and RA patients
(Martel-Pelletier et al., 2003).
There is also abundant evidence of upregulation of COX-2 in
the spinal cord in response to peripheral inflammation. COX-2
is present constitutively in the spinal cord, and COX-2 mRNA is
also induced in adjuvant induced arthritis in the rat (Beiche
et al., 1996; Hay et al., 1997), indicating a significant role in
the development of hyperalgesia and allodynia (Schaible et al.,
2006). Dolan et al. (2003) reported increased message and
COX-2 protein in lamina V dorsal horn neurones of sheep 1 day
after surgical inflammation (laparoscopy). Neugebauer and
Schaible (1990) described a role for the sensitization of spinal
neurones in acute arthritis in the cat, while Sluka et al.
(1994a) reported reduction of joint inflammation by dorsal rhi-
zotomy. Samad et al. (2001) and Veiga et al. (2004) described
(i) the pain hypersensitivity which arises in neighbouring unin-
jured tissue (secondary hyperalgesia) caused by increased neu-
ronal activity in the spinal cord and (ii) a syndrome comprising
diffuse muscle and joint pain, lethargy and anorexia. These
responses were attributable to widespread induction of COX-2
in the spinal cord. Suppression of both joint inflammation and
hyperalgesia by blockade of central sensitization pathways was
also demonstrated by Sluka et al. (1994b). These authors
reported reduced joint swelling and decreased hyperalgesia in
kaolin and carrageenan-induced models of arthritis, supporting
a reduction in rate of disease progression following blockade of
COX-2 in the spinal cord (Imamura et al., 2008; Read & Dray,
2008).
Comparison of mavacoxib and carprofen in in vitro COX-1 and
COX-2 assays
From the data in Table 3, it will be seen that potency ratios,
expressed at three levels (IC20, IC50 and IC80), for COX-1 and
COX-2 were similar for mavacoxib and carprofen as a control
drug (Lees et al., 2009). For both drugs, inhibitory ratios were
smallest for IC20s and greatest for IC80s; these differences are
attributable to a similar lack of parallelism of the COX-1 and
COX-2 inhibition curves for the two drugs. Based on these
data, mavacoxib and carprofen can probably be classified as
borderline between preferential and selective for COX-2 inhibi-
tion. It should be noted, however, that no single numerical
value for inhibition ratios can be assigned to distinguish
between preferential and selective action for COX-2, as this
depends on slopes of inhibition curves. Moreover, plasma con-
centrations achieved in vivo with recommended dosage of NSA-
IDs may be associated with inhibition of both isoforms, even
with preferential inhibitors (Lees et al., 2004; Giraudel et al.,
2005a). As shown above, a recommended dose of mavacoxib
of 2 mg/kg at 28-day intervals allows maintenance of plasma
trough concentration less than the IC20 for COX-1 inhibition.
The indicator in healthy animals of g.i.t. toxicity relative to
efficacy proposed by Giraudel et al. (2005a, 2009), IC20COX-1:
IC80COX-2, is of interest. It was, for mavacoxib and carprofen,
almost identical, 1.92:1 and 1.95:1, respectively (Table 3, Lees
et al., 2009). This suggests the likelihood of a broadly similar
level of safety for the g.i.t. relative to efficacy for the two drugs.
However, this would apply only if doses used clinically in the
dog provided plasma concentrations exerting similar magni-
tudes of inhibition of COX isoforms for the two drugs. More-
over, the comparison can provide only a reasonable
approximation to toxicity: efficacy ratios for two further rea-
sons. First, plasma concentrations will be subject to greater
within day variability for carprofen. For this drug, the PK
profile and dosage regimen dictate daily dosing, leading to
peaks and troughs of concentration during the 24-h dosing
interval. Such daily variations are slight for mavacoxib, the
concentration of which declines very slowly between the long
14-/28-day dosing intervals. Secondly, direct exposure from
oral dosing of g.i.t. mucosal cells occurs at 28-day intervals
after the second dose of mavacoxib, whereas for carprofen and
other NSAIDs, the local exposure occurs once or twice daily.
However, daily exposure of the g.i.t. mucosa to mavacoxib will
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occur due to its biliary excretion. If one assumes that all
mavacoxib is excreted via bile (i.e. worst case scenario), the
mavacoxib ‘dose’ exposed daily to the g.i.t. mucosa will be
based on plasma clearance and peak/trough concentrations
(see Table 2) as follows:
Maximal Daily amount of mavacoxib
excreted by the bile ¼ daily plasma clearance Cmax
or
Minimal Daily amount of mavacoxib
excreted by the bile ¼ daily plasma clearance Cmin
These equations can be solved with a daily plasma clearance
of 0.045 mL/min/kg 9 1440 min (Table 1) and (i) a maximal
plasma concentration of approximately 3 lg/mL and (ii) mini-
mal plasma concentration of approximately 1 lg/mL for a dose
of 4 mg/kg (Table 2). It is computed that (i) the maximal
amount of mavacoxib excreted daily by the bile is <200 lg/kg,
that is <10% of the monthly dose; and (ii) in the 24 h immedi-
ately before the next administration of mavacoxib (at trough
concentration), the amount of mavacoxib eliminated by the
bile is equivalent to approximately 1.5% of the recommended
maintenance dose. As only a small amount of mavacoxib is
eliminated in the bile and intestinal exposure is predicted to be
low, it can be hypothesised that this may produce better toler-
ability than for other NSAIDs such as carprofen that are admi-
nistered orally once daily, although currently there is no
evidence of that.
Observations within a large field safety and efficacy study
seem to support the better gastrointestinal tolerability of
monthly dosing compared with daily dosing; 195 of 1303
(15.0%) mavacoxib-treated dogs compared with 338 of 1295
carprofen-treated dogs (26%) exhibited digestive tract disorders
(Six et al., 2012). However, it should be noted that in this
unmasked study, the higher number of adverse events reported
for carprofen could be biased by the heightened owner’s aware-
ness to report gastrointestinal effects with a daily tablet admin-
istration.
Pharmacokinetics and adverse events
While the PK of mavacoxib provides a number of advantages
in the treatment of chronic OA, including potential higher
compliance, it has to be acknowledged that the inability to ter-
minate exposure with mavacoxib might be perceived as an
increased safety risk. A series of studies were conducted to
either alter enterohepatic recirculation or increase the rate of
metabolic clearance of mavacoxib. The results showed that
activated charcoal, cholestyramine, rifampin nor ursodiol had
no effect (M. Stegemann, personal communication). However,
within both pivotal registration and postmarketing studies, no
clinically relevant differences were observed between the safety
profile of monthly mavacoxib treatment compared with daily
carprofen treatment, when dogs were treated for up to
6.5 months (Payne-Johnson et al., 2009a,b, 2014; Six et al.,
2012).
Within a large postmarketing study (n = 2598 dogs), a total
of 595 mavacoxib-treated and 568 carprofen-treated dogs
remained on study for 194 days. The following observations
were made (Six et al., 2012). The mean time (days) to onset of
abnormal clinical signs was 80 and 76 for mavacoxib and car-
profen, respectively. The most commonly observed abnormal
clinical signs were digestive tract disorders (21%, 195 mavac-
oxib; 338 carprofen), systemic disorders (15%, 188 mavacoxib;
213 carprofen), and skin and appendage disorders (11%, 162
mavacoxib; 118 carprofen). The median duration of observed
clinical signs associated with diarrhoea was 3 and 2 days for
mavacoxib- and carprofen-treated dogs, respectively. Distribu-
tion (%, n) of adverse event seriousness was as follows: nonse-
rious (75%, 391 mavacoxib, 516 carprofen), lack of efficacy
(13%; 72 mavacoxib, 81 carprofen) and serious (12%; 72
mavacoxib, 78 carprofen).
Despite the fact that the effects of treatment with mavacoxib
cannot be terminated, field comparative data showed that the
safety profile of monthly mavacoxib and daily carprofen is sim-
ilar. The similarity in both frequency and nature of adverse
events observed after monthly (mavacoxib) and daily (carpro-
fen) dosing suggests that in many cases, supportive therapy
restores fluid balance and renal/g.i.t, blood supply in a way
that continued COX inhibition is no longer detrimental to the
animal. In other animals, the adverse effect itself, and that the
underlying disease that predisposed to it, is either sufficiently
severe and has resulted in irreversible organ damage such that
immediate cessation of drug therapy does not influence the
negative outcome of the case, or is self-limiting such that sup-
portive therapy is required for a period of time that is not
related to the duration of action of the NSAID.
As with any other NSAID, experimental target animal safety
studies do not usually detect renal toxicity because the animals
used are young healthy animals that remain well hydrated
throughout the dosing period. This was the case with mavac-
oxib at 15 mg/kg in a 6 month oral dosing study where no
definitive biochemical evidence of renal damage was detected
(M.J. Krautmann, J.F. Boucher. & M. Stegemann, personal
communication). Furthermore, in the registration field study at
the label dose of 2 mg/kg bw, the incidence of serious sus-
pected adverse product experiences affecting the kidneys was
very low for both mavacoxib and carprofen, when treatment
was continuously administered for up to 6.5 months (Six et al.,
2012; Payne-Johnson et al., 2014). Relatively short time to
onset of these renal adverse events, as well as pathological
findings, suggests that pre-existing renal pathology probably
predisposed to the adverse events. Nevertheless, it is acknowl-
edged that the clinical implications for renal health of adminis-
tering NSAIDs chronically to aged dogs with OA are unknown
and would require a comparison to placebo to control for the
background rate of development and progression of azotaemic
chronic kidney disease in this population of dogs. Such a study
would not be ethical, as these dogs require some form of pain
relief to improve their quality of life. Moreover, the relative
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safety of all COX-2 preferential drugs and indeed nonselective
COX inhibitors also, when administered chronically to dogs,
remains to be determined. Constitutive expression of both COX-
1 and COX-2 occurs in the canine kidney, suggesting that both
enzymes play a role in kidney physiology. Supporting hydra-
tion and maintaining extracellular fluid volume and blood
pressure are important measures that are advised to avoid
acute kidney injury and a sudden fall in GFR in dogs receiving
NSAIDs, and appropriate recommendations can be found on
the product label of both daily and monthly administered
coxibs.
Pharmacodynamic–pharmacokinetic correlations in canine models
with clinical endpoints
For a typical OA dog, 35 kg in weight and having a mavacox-
ib half-life of 40 days, the predicted Css,max is 2.08 lg/mL and
the predicted Css,min is 1.28 lg/mL. In this section, the effec-
tive/safe plasma concentrations actually obtained in in vivo
studies conducted in the dog are considered. For this purpose,
total plasma concentration is considered, as this is the driving
concentration for all local concentrations, including the CNS
local concentration.
Analgesic efficacy of mavacoxib in a carrageenan-induced
metacarpal footpad lameness model was achieved with a
plasma mavacoxib concentration of 0.454 lg/mL at day 22
after mavacoxib dosing for walking lameness. Significant effi-
cacy for both walking and standing lameness was obtained at
day 15, when plasma concentration was 0.766 lg/mL. It is
reasonable to assume at least similar efficacy prior to 22 days
(walking lameness) and before 15 days (both walking and
standing lameness), with the higher plasma concentrations at
the earlier times.
In an acute synovitis model, excellent analgesia was
obtained 30 days after dosing, when mean mavacoxib plasma
concentration was 0.411 lg/mL (Table 4, Lees et al., 2009).
The data from these footpad and synovitis models may be com-
pared with plasma mavacoxib concentrations for IC50 and IC80
for COX-2 of 0.394 and 1.28 lg/mL, respectively. Thus, excel-
lent analgesia was achieved 30 days after dosing in the synovi-
tis model with a concentration approximately equal to the IC50
for COX-2 (Tables 3 & 4). The mavacoxib dosage regimen of
2 mg/kg at 28-day intervals, selected for clinical use, provided,
in a clinical study in OA dogs, trough concentrations of
0.52 lg/mL (14 days after dose 1) and 1.11 lg/mL (28 days
after dose 5). Therefore, because of the differing PK profiles
between the preclinical and clinical dogs, the trough concen-
trations in the OA clinical population exceeded those providing
good efficacy in the synovitis model and also exceeded the IC50
for COX-2 at all times.
Integration of trough concentrations of mavacoxib in osteoarthritic
dogs with in vitro assays of COX inhibition
A NSAID dosage regimen that provides minimal risk for g.i.t.
toxicity and inhibition of clotting side effects should preferably
not exceed IC20 for COX-1 inhibition for most if not all of the
interdose interval, that is a concentration of the order of
2.46 lg/mL for mavacoxib.
Trough plasma concentrations of mavacoxib in the two clini-
cal studies in OA dogs reported by Cox et al. (2011) are pre-
sented in Table 5. At the 2 mg/kg dosage, the maximum
trough concentrations were obtained after the 5th dose
(1.1  0.50 lg/mL): maximum plasma concentrations were
not reported in these trials but, using the 1.6 factor for the Css,
max/Css, min ratio as derived above, the corresponding maxi-
mum plasma concentration is predicted to be 1.76  0.8 lg/
mL. These values are consistent with those predicted for typical
OA dogs of 35 kg BW and having a half-life of 40 days, with a
Css, max of 2.08 lg/mL and a predicted Css, min of 1.28 lg/mL.
In fact, in no dog at any sampling time did the trough plasma
concentration exceed 2.46 lg/mL (the IC20 for COX-1 inhibi-
tion) for a maintenance dose of 2 mg/kg. Moreover, based on
computer simulation of plasma concentration in a dog with a
t½ exceeding 80 days (and not attaining steady-state after five
doses), receiving 2 mg/kg mavacoxib, the peak concentration
after the fifth dose was <2.46 lg/mL.
In Study 1 of the population PK study of Cox et al. (2011)
at 4 mg/kg mavacoxib dosage, the highest trough mean con-
centration of mavacoxib in plasma was 2.60 lg/mL after the
seventh dose (Table 5), which is close to the IC20 for COX-1 of
2.46 lg/mL (Table 3). Considering the 1.6 scaling factor, the
Table 4. Plasma mavacoxib concentrations and visual analogue scores (VAS) assessed at 3 h* in a canine acute synovitis model
Treatment and dose
(n = 10/group) (mg/kg)
Plasma concentration†
Mean  SD (lg/mL)
VAS value†
LSM (95% CI)
VAS difference
from placebo
VAS statistics‡
P-value
0 (placebo)a 0 8.35 (6.60, 10.10) – –
0.5a 0.084  0.053 6.74 (4.92, 8.56) 1.61 0.116
1.0a 0.114  0.064 7.62 (5.87, 9.37) 0.73 0.457
2a 0.249  0.132 6.95 (5.20, 8.70) 1.40 0.157
4b 0.411  0.220 3.97 (2.22, 5.72) 4.38 0.001
6b 0.697  0.452 3.06 (1.31, 4.81) 5.29 0.001
LSM, least square mean; CI, confidence interval. For comparative purposes note that IC50 COX-2 = 0.394 lg/mL and IC80 COX-2 = 1.280 lg/mL
in whole blood assays (see Table 3). Treatment groups sharing the same superscript a or b were not significantly different (P > 0.05). *Inflamma-
tion induced in stifle joint at zero time by intra-articular injection of cytokines induced by lipopolysaccharide in a canine macrophage cell line.
†VAS values and mavacoxib concentrations determined 30 days after a second dose of mavacoxib. ‡Difference from placebo.
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predicted highest maximum plasma concentration would have
been 4.16 lg/mL, that is exceeding both the IC20 for COX-1
and IC80 for COX-2 inhibition. Therefore, it seems very likely
that the dose of 4 mg/kg was supramaximal, that is higher
than required to achieve effective therapy.
In clinical trials, the percentages of animals improved were
93 and 79 for the 2 and 4 mg/kg dosage, respectively (Payne-
Johnson et al., 2009a,b). For the 2 mg/kg dosage group, both
owner and veterinary assessments indicated noninferiority to
the control dogs receiving carprofen; 93.4% improvement in
the mavacoxib group compared with 89.1% in the dogs receiv-
ing carprofen for owner assessment. In addition, the improve-
ment in response to mavacoxib increased over the first
6 weeks after commencing therapy and was maintained at a
plateau level thereafter. Compared with pretreatment, pain was
reduced by 39% after 14 days and by 65% after 135 days
from commencement of treatment, when corresponding plasma
trough concentrations were 0.52 and 1.11 lg/mL.
Summary of pharmacological properties of mavacoxib relevant to
treatment of canine OA
A classical dose determination study employing an acute syno-
vitis model in Beagle dogs indicated a mavacoxib dose of
4 mg/kg to be necessary to exhibit pronounced efficacy. Popu-
lation PKs derived from a field study in which the dose of
4 mg/kg was tested indicated that the plasma elimination half-
life was longer in client-owned osteoarthritic dogs than in
young healthy Beagle dogs (Cox et al., 2010, 2011). This latter
finding made it possible to reduce the dose from 4 to 2 mg/kg
and thereby increasing the safety margin while maintaining
clinical efficacy. Mavacoxib is licensed for the use for the treat-
ment of pain and inflammation in canine OA, when a treat-
ment period exceeding 1 month is indicated. The dosage
schedule is 2 mg/kg on days 1 and 14, and then, the same
dosage is administered at 28-day intervals; a treatment cycle
should not exceed seven doses. The product literature recom-
mends that clinicians should observe a treatment-free period of
at least 1 month before administration of another NSAID after
mavacoxib treatment. There are several factors to be consid-
ered, when using mavacoxib as an agent for the control of
pain and acute inflammatory flare-ups in dogs with OA:
a) Nonsteroidal anti-inflammatory drugs are the drugs of
choice for the therapy of canine OA; several have been
licensed and all, with the exception of mavacoxib, are rec-
ommended for dosing once or twice daily (Sanderson et al.,
2009; Innes et al., 2010). Once or twice daily dosing fre-
quency is dictated by the short to intermediate terminal
half-lives. Clinically, NSAIDs have been used either to con-
trol short-term acute flare-ups in OA or for continuous
management over periods of weeks or months. Autefage
and Gossellin (2007) reported the maintenance of clinical
improvement in OA dogs on long-term carprofen therapy.
Similar findings have been reported for mavacoxib (vide
infra) and may be reflected in improved mobility, reduction
in disease muscle atrophy and possibly reduced rate of dis-
ease progression (Sanderson et al., 2009; Innes et al.,
2010). In terms of therapeutic benefit, there are theoretical
efficacy advantages arising from maintained plasma con-
centrations for mavacoxib, in comparison with the peaks
and troughs of concentration provided by daily dosing with
other NSAIDs (vide supra). However, clinical efficacy can be
established only in well-designed comparative clinical trials
with effective monitoring of responses and, in this regard,
similar efficacy has been demonstrated for carprofen daily
and mavacoxib monthly dosing.
b) The inhibition of COX-2, at a level approaching or exceed-
ing 80% throughout a treatment period of up to 6 months,
should ensure for mavacoxib an adequate level of pain con-
trol throughout. It is theoretically possible that, even with
well-maintained plasma concentrations, there could be
development of tolerance to the actions of the drug at the
molecular level [pharmacodynamic (PD) tolerance]. How-
ever, this seems unlikely, based on both theoretical and
clinical grounds. Drug–enzyme interactions are rarely asso-
ciated with tolerance and owner and veterinary assess-
ments of efficacy gave no indication of reduced effect with
duration of treatment. The slow rate of decrease in plasma
concentration of mavacoxib over the dosing interval should
ensure steady maintenance of analgesia.
c) The signs of OA are commonly intermittent rather than
continuous. Both laboratory animal studies and clinical
experience suggest that continuous analgesic therapy
breaks the cycles of acute flare-ups to provide pain control
and increased mobility, leading to maintenance of muscle
mass, increased joint stability and possible slowing of dis-
ease process (Sluka et al., 1994b; Sanderson et al., 2009).
The maintenance of an effective plasma concentration of
mavacoxib throughout the interdose interval will ensure
that tissue (including synovial fluid) concentrations are in
equilibrium with those in plasma and thereby minimize
variability in concentrations at the site of action.
d) The persistent and prolonged inhibition of prostanoid pro-
duction by COX-2 enzymes caused by mavacoxib may have
therapeutic advantages related to efficacy over intermittent
Table 5. Plasma mavacoxib trough concentrations [mean  SD (n)] in
osteoarthritis dogs after administration of up to seven doses in Study
1* and five doses in Study 2†
Dose Time after dosing (days)
Mavacoxib concentration (lg/mL)
Study 1 Study 2
1 14 1.39  0.40 (210) 0.52  0.15 (61)
2 45 1.91  0.74 (203) 0.73  0.30 (62)
3 75 – 0.88  0.41 (60)
4 105 2.45  1.19 (185) 0.97  0.47 (58)
5 135 – 1.11  0.50 (56)
6 165 2.58  1.30 (65) –
7 195 2.60  1.58 (98) –
*Dosage = 4 mg/kg; †Dosage = 2 mg/kg.
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inhibition. While such persistent inhibition could to a large
degree be achieved by constant administration of short-act-
ing NSAIDs, it has to be acknowledged that reduced com-
pliance of daily administration as well as the constantly
changing blood concentrations after daily administration
may not provide the same level of stable inhibition as long-
acting NSAIDs such as mavacoxib. Repeated stimulation of
the nervous system with pain stimuli leads to the phenom-
ena of hyperalgesia and allodynia, which occur through
adaptive responses in protein expression in peripheral and
central neurones, thereby changing how these systems
perceive sensory stimuli. Continuous and persistent inhibi-
tion of prostanoid production at sites of chronic inflamma-
tion, such as joints involving degenerative joint disease,
may lead to more effective control of these processes. From
the central and peripheral mechanisms contributing to hy-
peralgesia and allodynia, it is clear that changes in protein
expression as a result of inflammatory mediator activation
of neuronal pathways underlie complex mechanisms of
central and peripheral hyperalgesia. Thus, it is likely that
relatively short-term activation of prostanoid receptor path-
ways could lead to longer lasting hyperalgesic effects
through, for example the increase in density of tetrodo-
toxin-resistant sodium channels or enhanced transmission
of pain signals in the spinal cord. The duration of this effect
will depend on the rate of neuronal channel or receptor
degradation. If clinical compliance on dosing frequency
with short-acting NSAIDs is relatively poor, as it will be on
occasions, intermittent formation of prostanoids could be
sufficient to activate these pathways and perpetuate the
phenomenon of hyperalgesia (central or peripheral) possibly
even leading to the wind-up phenomenon.
e) The selected clinical dose (2 mg/kg) of mavacoxib inhibits
the COX-1 isoform to a much lesser degree than that of
COX-2, comprising 20% or less inhibition of the former at
trough concentrations. This may minimize side effects on
the g.i.t. and blood clotting mechanisms attributable to
inhibition of this isoform. However, it is possible that
hypercoagulable states might be worsened. Moreover, it
should be noted that COX-2 is constitutive in several tis-
sues and, as with other selective COX-2 inhibitors, the per-
sistent action of mavacoxib might inhibit certain
physiological or pathophysiological functions under certain
conditions. The possible disadvantage of mavacoxib, poten-
tially, is its irreversibility, should side effects occur in clini-
cal use in an individual patient; treatment will have to be
symptomatic. Nevertheless, clinical experience with mavac-
oxib to date would suggest that the prevalence, duration
and outcome of suspected adverse reactions, occurring in
dogs receiving mavacoxib, is no different to those occurring
in dogs treated with carprofen long term on a daily dosage
regimen (Six et al., 2012).
f) The side effect of NSAIDs of greatest incidence and severity,
comprising damage to the upper g.i.t. arising from their
irritant actions, may be minimized by the long dosage
intervals (14 days after dose 1 and 28 days thereafter) of
orally administered mavacoxib. Damage may arise from
three major causes: (i) exposure of the mucosal lining of
the stomach and intestine to high local concentrations after
dosing and prior to absorption, (ii) exposure via local blood
flow containing the drug and (iii) local mucosal exposure
through daily drug secretion in bile (Whittle, 2004). With
mavacoxib, the local exposure associated with dosing is
intermittent and therefore reduced in comparison with the
once or twice daily dosage regimens required for other
NSAIDs licensed to treat canine OA. However, exposure to
mavacoxib through the blood supply is continuous rather
than phasic. Moreover, exposure to semicontinuous low
concentrations is likely as a consequence of biliary excre-
tion. On the other hand, for those drugs with daily dosing
recommendations but with short terminal half-lives, there
is a potential advantage of daily periods of low exposure of
the g.i.t. from all three sources.
g) The low frequency of dosing with mavacoxib should ensure
good owner compliance with the recommended dosing
schedule. As discussed by Lees and Maddison (2006), there
is evidence of poor compliance with dosing schedules in
canine medicine, especially when oral administration is
more than once daily. In fact, Payne-Johnson et al. (2009a,
b) demonstrated that the dosage regimen of 2 weeks
between first and second and 4 weeks between subsequent
doses did provide greater compliance than once daily
NSAID dosing. Whereas noncompliance with number of
and/or interval between doses might raise welfare/efficacy
issues for short-acting NSAIDs, a delay of 2–3 days in
administering the next dose of mavacoxib should not have
significant implications for efficacy.
CONCLUSION
Mavacoxib is a novel NSAID, with a preferential action on the
COX-2 isoform of COX and a long duration of action. The dos-
age schedule of mavacoxib for clinical use has been determined
by owner and veterinary clinical assessments and is supported
by integration of PK and PD preclinical data with clinical
responses in canine disease models and in dogs with naturally
occurring OA. The dosage regimen has been further confirmed
by correlating levels of inhibition of COX isoforms in in vitro
whole blood assays with plasma concentrations of mavacoxib
achieved in OA dogs. Integration of PK and PD data suggests
that the recommended dosage regimen of 2 mg/kg bw once for
14 days, followed by administration at monthly intervals, is
optimal for both efficacy and safety perspectives and is further
confirmed by clinical field studies.
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